RussianPatents.com

Ointment for skin pecilomycosis

IPC classes for russian patent Ointment for skin pecilomycosis (RU 2475245):
Another patents in same IPC classes:
Agent antiactinomycilline for treating actinomycosis and necrobacillosis in farm animals Agent antiactinomycilline for treating actinomycosis and necrobacillosis in farm animals / 2475244
Invention relates to veterinary science. The agent contains, wt %: wildflower honey 3.0-5.0, pine turpentine 5.0-8.0, melted (cow) butter 12.0-15.0, anaesthesine 0.5-1.0, glycerol 0.5-1.5, ethanol 20.0-25.0, potassium iodide 2.0-2.5, salicylic acid 3.0-5.0, 9% vinegar 6.0-8.0, Novocaine (powder) 1.0-1.5, distilled water - the rest.
Method of producing heterocycle-substituted pyridine derivatives Method of producing heterocycle-substituted pyridine derivatives / 2474581
Invention relates to a method of producing heterocycle-substituted pyridine derivatives of general formula (I) by reacting a compound of general formula (III) with a compound of formula (II) in a solvent and in the presence of a catalyst based on palladium or a base, where R1, R2, X, Y, Q, A, Z, R, R3 and R4 are described in the claim.
Stable dosage form for local application containing voriconazole Stable dosage form for local application containing voriconazole / 2472510
Dosage form for local application in the form of cream or ointment contains as effective amount of voriconazole or its pharmaceutically acceptable salt, or a pharmaceutical carrier. Said dosage form of voriconazole contains max. 3 wt % of water. What is also described is a method for preparing the dosage form of voriconazole for treating local and non-systemic mycotic infections in an individual.
Polypeptide compound Polypeptide compound / 2470939
Polypeptide compounds contain cyclohexyl methyl amino groups or piperidyl methyl amino groups in the structure.
Antibacterial peptides Antibacterial peptides / 2468033
Present invention relates to peptides having antibacterial and endotoxin-neutralising activity, having general formula (Xaa1)M-(Xaa2)o-Xaa3-(Xaa4)p-(Xaa5)Q-(Xaa6)M-(Xaa7)R-(Xaa8)S.
Stable radicals having bactericidal and fungicidal activity Stable radicals having bactericidal and fungicidal activity / 2465279
Invention relates to novel heterocyclic radicals of formulae and , having bactericidal and fungicidal properties, which can be used in veterinary and medicine, as well as labels when investigating metabolic routes of medications in living organisms.
Quinazoline derivative and pharmaceutical preparation Quinazoline derivative and pharmaceutical preparation / 2464263
Invention relates to a quinazoline derivative of general formula [1], or a pharmaceutically acceptable salt thereof [1], where R1-R6 assume values given claim 1, except compounds in which R5 is hydrogen and R6 is -NH2. The invention also relates to a pharmaceutical composition having the activity of an antipruritic agent, containing as an active ingredient said quinazoline derivative or pharmaceutically acceptable salt thereof.
Preparation reganide for treating and preventing diseases in mammals / 2464025
Invention refers to a preparation for treating and preventing diseases in mammals on the basis of a germanium-organic compound of formula C24H10N3O13Ge which is a pyridine dicarboxylic acid derivatives and possess immunomodulatory, antibacterial, antimycotic and anthelminthic activity.
Compositions and methods of treating zygomycosis and other fungoid diseases Compositions and methods of treating zygomycosis and other fungoid diseases / 2464024
Invention concerns the use of compositions for preparing a drug for treating or preventing zygomycosis. The compositions contains at least one iron-chelating compound. Also, the compositions may additionally contain at least one antimycotic agent. The iron-chelating compounds are represented by the compounds other than siderophore or xenosiderophore with respect to the given fungoid diseases, namely deferiprone and deferasirox. The antimycotic agents being parts of the compositions may contain polyene azol or echinocandin antimycotic agents.
Cyclic antimicrobial peptides Cyclic antimicrobial peptides / 2463308
Invention relates to cyclic cationic peptides and use thereof in treating fungal infections.
Pharmaceutical composition containing chondroitin sulphate and/or hyaluronidase and liposome for local application / 2473350
Present invention refers to medicine, namely to a pharmaceutical composition for local application. The composition contains chondroitin sulphate, hyaluronidase, glucosamine hydrochloride, liposome and pharmaceutically acceptable carriers and excipients in the amounts specified in the patent claim. The composition may additionally contain capsaicin.
Ointment for treating bitten wounds / 2473329
Invention relates to pharmaceutical industry, to creation of wound-healing ointment. Ointment for treatment of bitten wounds includes lidocaine hydrochloride, sea-buckthorn oil, water-free lanolin, medicinal purified Vaseline, metronidazole, clindamycin, rifampicin and trombolisin.
Medication for treating purulent wounds in animals / 2473328
Invention relates to field of veterinary, in particular to veterinary surgery, and can be applied in treatment of purulent wounds in animals. Medication for treatment of purulent wounds in animals includes active substance and ointment base - polyethylene oxide-1500 and polyethyl oxide-400. Active substance is a product of dry sublimation of birch chaga mushroom, mixed with polyethylene oxide-400 and polyethyleneoxide-1500 in ratio 1.25:4:1 respectively at temperature 39…4°C.
Stable dosage form for local application containing voriconazole Stable dosage form for local application containing voriconazole / 2472510
Dosage form for local application in the form of cream or ointment contains as effective amount of voriconazole or its pharmaceutically acceptable salt, or a pharmaceutical carrier. Said dosage form of voriconazole contains max. 3 wt % of water. What is also described is a method for preparing the dosage form of voriconazole for treating local and non-systemic mycotic infections in an individual.
Method for integrated treatment of maxillofacial abscesses and phlegmons in children by ointment with furacilin, lidocaine and dibunol / 2470629
Offered invention refers to medicine, namely dentistry, and may be used for treating children suffering maxillofacial abscesses and phlegmons. That is ensured by opening of a suppurative focus, wound bathing and drainage. With underlying conventional antibacterial therapy, an ointment containing furacilin, lidocaine and dibunol as active agents and a styrene maleic anhydride copolymer, Lutrol F-127 and purified water in certain proportions as an ointment base is introduced in the suppurative cavity. Furacilin - 0.2, Lidocaine - 5.0, Dibunol - 5.0, Styrene maleic anhydride copolymer - 2.0, Lutrol F-127 2.0 and Purified water to 100.0.
Pharmaceutical composition for transdermal application for increase of drug activity and decrease of side effects Pharmaceutical composition for transdermal application for increase of drug activity and decrease of side effects / 2469706
Phospholipid emulsion contains lecithin with the phosphatidylcholine content min. 60%, ethanol, water and diclofenac sodium in the amounts specified in the patent claim. The phospholipid emulsion represents liposomes (nanosomes) of a mean diameter of 20 to 500 nm. The composition is used for the liposomal introduction of biologically active substances and/or drugs into a human body. The emulsion nanosomes may additionally contain one or more substances specified in a group: carotinoids, flavonoids, vitamins, resveratrol, vitamin-like substances, cartilage protectors, amino acids, preserving agents.
Method for preparing free autograft for burn wound / 2466714
10 minutes before grafting, donor skin 0.2-0.3 mm is coated with Tisol gel mixed with ozonised sea buckthorn oil. Then, 10 minutes later, the residual mixture is removed; the donor skin surface is treated with spirits, and grafting procedure is started.
Method for producing biopreparation ferrigel / 2466713
Method for producing a biopreparation involves mixing of ferric oxyhydroxide with a water-soluble polymers and ultrasonic treatment of the suspension differing by the fact that there are used ferric oxihydroxide gel (FOH-gel) recovered at the stages of underwater deironing, the water-soluble polymer, and additionally glycerol is introduced in the following proportions, wt %: FOH-gel 50-60; water-soluble polymer 2.5-3; glycerol 10-15; water to 100. The water-soluble polymer is presented by a polymer specified in a group of polyvinyl alcohol (PVA), polyethylene glycol (PEG), polyvinylpyrrolidone (PVP) or polyacrylamide (PAA). The biopreparation possesses wound healing, bactericidal, regenerative and adsorption properties.
Medication for treating purulent wounds / 2465899
Invention relates to pharmaceutical industry, in particular to medication for treatment of purulent wounds by method of photodynamic therapy. Medication for treating purulent wounds by method of photodynamic therapy in form of gel, which includes zinc polycholinyl phthalocyanine, hydroxyethylcellulose, dimethylsulfoxide or benzalconium chloride (alkylbenzyldimethylammonium chloride), block-copolymer of ethylene oxide and propylene oxide or polyethyleneglycol, water, taken in specified quantity. Medication for treatment of purulent wounds by method of photodynamic therapy, representing film, obtained by drying of gel described above.
Homeopathic composition for treating mastopathy, painful inflations, premenstrual inflamed breast warts, as well as benign neoplasms / 2463068
Invention refers to medicine, namely preparing a homeopathic ointment with wide spectrum of action. The homeopathic composition for treating mastopathy, painful inflations, premenstrual inflamed breast warts, as well as benign neoplasms represents an ointment containing celandine, cedar, wild rosemary, pokeberry, plantain essences, graphite D6, fumitory D6 dilutions, and arespol-margarine-lanoline base.
Substituted sulphonamides, method for production thereof, medicinal agents containing said sulphonamides and use thereof Substituted sulphonamides, method for production thereof, medicinal agents containing said sulphonamides and use thereof / 2474574
Invention relates to use of substituted sulphonamides of general formula (I) where R1 is CO or SO2, R2 is NH or O, R includes a tertiary diC1-4alkylamine group in which alkyl fragments are identical or different, or an amino group whose alkyl groups together form a 5, 6 or 7-member ring with saturated bonds or the ends of the alkyl fragments are bonded to an O heteroatom, or R is 4-(N,N-diethylaminoethoxy)benzyl, where R1 is SO; and R2 is NH; or R is 4-[N-(morpholinopropyl)sulphamoyl]phenyl, where R1 is CO and R2 is NH, n is the number of carbons in the connecting aliphatic chain, where n is equal to 0, 2 or 3; and/or physiologically acceptable salts thereof in production of a medicinal agent for treating glaucoma. The invention also relates to substituted sulphonamides of formula (Ia) (where values of radicals are given in the claim) and physiologically acceptable salts thereof, a method for production thereof and a medicinal agent based thereon, for treating eye diseases.

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmacy, namely agents based on herbal raw material possessing pecilomycotic action. A sage kerosene ointment contains kerosene extract of air-dried sage leaves, Vaselin taken in certain proportions.

EFFECT: ointment possess effective antimycotic action.

4 tbl

 

The invention relates to the pharmacy, and in particular to means on the basis of medicinal plants with antifungal activity.

Paecilomyces is a fungal disease caused by infection with various types of conditionally pathogenic fungi of the genus Paecilomyces, described in Mahonoy (Akhunov A.M., Shustov VI Clinical and immunological characteristics of paecilomyces // Clinical medicine. - 1991. No. 3. S-115).

The main reservoir paecilomyces infection in nature is the soil and in the human body - blood. The main pathways paecilomyces infection - respiratory, oral and transplacental. Mushrooms of the genus Paecilomyces saprophyticus in the soil as mycelium forms, and when injected into a human or animal are transformed into tissue parasitic form of Sterol. Mature spherule these mushrooms - rounded calf with dual-circuit shell, within which are enclosed endospores. The size of the Mature Sterol range from 10 to 29 μm, endospore from 0.3 to 1.5 μm. The disease is accompanied by severe lesions in vital organs, which can lead to death.

In officinales medicine, there are many plants with antifungal activity, one of them is the sage leaves (Folia Salviae), which contain from 0.5% to 2.5% essential oil in the composition is otorongo is cineole (up to 15%), l-α-thujone, d-β-thujone, d-α-pinene, Calvin, d-borneol (8-14%), d-camphor, adren. In addition, the leaves contain tannins, flavonoids, ursolic and oleanolic acid, vitamin e, nicotinic acid, bitter, volatile, uvaol, paracetanol. In the work Dragan T. (Chemical Composition and Antimicrobial Characteristic of the Essential Oils Obtained from the Flower, Leaf and Stem of Salvia officinalis L. // Journal of Essential Oil Research. Vol.14, N6, 2002) studied the antibacterial activity of the oils on the following microorganisms: Escherichia coli, Salmonella enteritidis, Pseudomonas aeruginosa, Bacillus subtilis, Staphylococcus aureus, Sarcina lutea, Candida albicans, Saccharomyces cerevisiae, Aspergillus niger. It is revealed that the concentration of oil, which stopped the growth of B. Subtilis, was 2%, St. Aureus - 0,2%, E. coli and P. Aeruginosa - 4%. Other strains of microorganisms oil also had antibacterial action.

Object of the invention is an ointment for the treatment of skin paecilomyces.

The problem is solved ointment for the treatment of skin paecilomyces, characterized in that it contains from 9.0 to 10.0 g of kerosene extract obtained by maceration within two weeks of the dried leaves of Salvia officinalis and aviation fuel in the ratio of 1-4:5, and vaseline to 100.0.

The following example shows how to get the ointment.

Method of maceration in the ratio of raw material and extractant 1-4:5 receive kerosene extract of the dried leaves of Salvia officinalis (humidity h is more than 14%). In a glass vessel of dark glass with a tight lid placed 5,0 dried ground leaves of Salvia officinalis (particle size 10 mm), pour aviation kerosene in the amount of 25.0 and infused for 2 weeks in a dark place with occasional stirring. Then, the resulting extract is filtered.

Kerosene extract of the dried leaves of Salvia officinalis is a clear liquid dark green colour with a pungent characteristic odor, which provides an additional 5 unidentified compounds, compared with an alcoholic extract of Salvia officinalis.

Next, in a water bath melt some vaseline (40,0) and dissolve in it a kerosene extract, Salvia officinalis (10,0). Then add the remainder of vaseline (to 100.0) and stirred until a homogeneous consistency.

Test the obtained ointment toxicity.

The experiments were carried out on randombred white albino male rats (weighing 210-220 g). Groups of rats was 30 individuals (10 of each study period). Ointment sage-kerosene and clean sage-kerosene extract was applied to the shaved skin of animals in the amount of 0.2 g daily for 30 days. The area of application was 1 cm2. During the first 14 days of the experiment at ptopic the s rats was not registered deviations from control in all biochemical parameters. However, after 30-day exposure to kerosene sage extract was observed reversible signs of local irritation in the form of hyperemia of the skin and the appearance of thin crust. When applying the test ointments such phenomena wore a single character. In a study of rats after application of kerosene extract of sage observed changes in hematological parameters (reduction of the color indicator and the acceleration of blood clotting). In the group of rats to which was applied the test ointment, fluctuations in hematological and biochemical parameters did not differ from the control groups of animals.

Test paecilomyces activity was performed, comparing the effectiveness of sage-kerosene ointment with nizoralbuy ointment used for skin paecilomyces. Comparison of ointments was carried out on 60 outbred white rats-males weighing 210-230 g

In total, the 39-x rats in the experiment developed skin paecilomyces. Before treatment was performed hematological and biochemical analysis of the blood of animals (table 1, 3). As can be seen from the given data, in rats, infected skin paecilomyces marked in the blood decrease in the number of erythrocytes, hemoglobin, total protein and white blood cells, increase in the number of eosinophils, glucose, the activity of Alat, ASAT, alkaline phosphatase.

17 rats treated - sage-kerosene ointment is, and 14 rats - product comparison - nizoralbuy ointment.

Within 30 days daily from 17 rats smeared sage-oil ointment in a thin layer in the morning and in the evening the affected skin. All animals disappeared purple areas and has cured, the same effect obtained in the treatment of 14 rats nizoralbuy ointment. Animals normalized blood in the group that was treated sage-oil ointment. In the group of rats treated with nizoralbuy ointment, came normalization of blood counts (tables 2, 4). Thus, unlike nizoralbuy ointment sage-kerosene ointment provided impact not only on the local site of infection, but the lesions that developed in the lungs.

Table 1
The results of the study of the blood of rats infected with paecilomyces to use sage-kerosene ointment.
Blood counts To use ointment
control group, n=8 the test group, n=17
Hemoglobin, g/l 84,30±0,15 82,20±2,75
Erythrocytes, x 10sup> 12l 3,90±0,18 3,85±0,45
The leukocyte count, ×109l 7,45±0,54 7,54±0,42
Basophils, % 1,10±0,20 2,10±0,20
Eosinophils, % a 9.60±0,30 9,50±1,70
Stab, % 3,70±0,40 3,80±0,30
Segmented, % 20,50±0,90 19,50±0,80
Lymphocytes, % 61,6±1,40 61,90±1,40
Monocytes,% 3,50±0,30 4,20±0,30
Glucose, mmol/l of 9.56±0,40 9,23±0,30
Total bilirubin, µmol/l 47,70±0,50 46,40±0,30
Urea, mmol/l 1,26±0,20 1,32±0,30
Alat, mmol/h·l 4,59±0,30/td> 4,75±0,20
AST, mmol/h·l 3,35±0,40 3,43±0,30
Alkaline phosphatase, mmol/h·l of 11.15±0,75 11,24±1,40

Table 2
The results of the study of the blood of rats infected with paecilomyces, when studying the effect sage-kerosene ointment.
Blood counts After the 30-day application of the new ointment
control group, n=8 the test group, n=17
Hemoglobin, g/l 86,70±3,50 149,50±5,10
Red blood cells, ×1012l 4,40±0,50 of 7.90±0,40
The leukocyte count, ×109l 7,50±0,50 12,70±1,40
Basophils, % 2,20±0,30 1,70±0,40
Eosinophils, % 0,50±1,20 3,50±0,20
Stab, % 3,70±0,30 3,50±0,40
Segmented, % 18,30±0,40 26,70±1,70
Lymphocytes, % 61,40±1,50 63,40±1,70
Monocytes, % 3,70±0,20 3,30±0,40
Glucose, mmol/l of 10.76±0,50 5,56±0,25
Total bilirubin, µmol/l 39,20±0,60 85,70±0,40
Urea, mmol/l 1,23±0,20 3,20±0,40
Alat, mmol/h·l 5,12±0,50 1,87±0,40
AST, mmol/h·l 4,12±0,40 0,75±0,07
Alkaline phosphatase, mmol/h·l to 15.06±1,60 2,89±0,35

Table 3
The results of the study of the blood of rats infected with paecilomyces, before applying nizoralbuy ointment (product comparison).
Blood counts To use ointment
control group, n=8 the test group, n=14
Hemoglobin, g/l 82,±0,20 88,40±3,10
Red blood cells, ×1012l 4,30±0,30 3,80±0,30
The leukocyte count, ×109l 7,56±0,50 to 8.57±0,52
Basophils, % 2,30±0,20 2,80±0,40
Eosinophils, % at 8.60±0,50 8,50±1,30
Stab, % 2,70±0,30 2,70±0,30
Segmented, % 20,40±1,20 22,10±1,20
Lymphocytes, % 61,70±1,40 57,70±1,80
Monocytes, 3,90±0,50 4,20±0,40
Glucose, mmol/l 8,15±1,45 of 10.47±0,70
Total bilirubin, µmol/l 47,60±0,50 53,20±0,50
Urea, mmol/l 1,29±0,50 1,35±0,40
Alat, mmol/h·l 4,55±0,35 of 5.29±0,70
AST, mmol/h·l 3,35±0,40 the 3.65±0,40
Alkaline phosphatase, mmol/h·l of 10.47±0,70 of 9.45±0,70

Table 4
The results of the study of the blood of rats infected with paecilomyces, when applying nizoralbuy ointment (product comparison).
Blood counts After the 30-day application of nizoralbuy ointment
control group, n=8 the test group, n=14
Hemoglobin, g/l 85,20±4,10 87,50±2,70
Red blood cells, ×1012l 4,50±0,40 4,30±0,50
The leukocyte count, ×109l of 7.60±0,50 8,10±0,50
Basophils, % 2,20±0,30 2,40±0,30
Eosinophils, % 10,70±1,20 10,70±1,20
Stab, % of 3.60±0,40 4,10±0,40
Segmented, % 18,80±0,70 21,70±1,30
Lymphocytes, % 61,90±1,70 57,20±1,70
Monocytes,% 3,20±0,40 4,70±0,50
Glucose, mmol/l 9,36±0,60 9,49±0,70
Total bilirubin, µmol/l 39,20±0,80 49,20±0,80
Urea, mmol/l 1,35±0,40 1,65±0,50
Alat, mmol/h·l 4,75±0,50 5,15±0,50
AST, mmol/h·l 3,25±0,20 3,42±0,30
Alkaline phosphatase, mmol/h·l 12,42±1,30 9,95±0,70

In addition, for a variety of purposes were infected from patients paecilomyces animals 40 white mice weighing 18-20 g in a variety of ways of introducing the culture of paecilomyces mushrooms: intraperitoneally, subcutaneously and just inside. 37-mi mice were amazed mushrooms tails. They were divided into three groups: 7 was a control that was not treated (the first group), 12 mice, the tails of which were processed by nizoralbuy ointment (the second group), 18 mice tails are smeared sage-oil ointment. Within 5 days all 7 mice of the first group died from paecilomyces. In the second group died 7 mice at 6 and day 7 after treatment, in the third group all 18 mice recovered. Therefore, sage-kerosene ointment has not only the effect of treatment of skin paecilomyces, but also a strong antifungal activity.

Ointment for the treatment of skin paecilomyces, characterized in that it contains from 9.0 to 10.0 g of kerosene extract obtained is about at the insistence within two weeks of the dried leaves of Salvia officinalis and aviation fuel in the ratio of 1-4:5 and vaseline to 100.0 g

 

© 2013-2015 Russian business network RussianPatents.com - Special Russian commercial information project for world wide. Foreign filing in English.